Diagnosis and treatment of Helicobacter pylori

Current Treatment Options in Gastroenterology

Volumn 8, Issue 2, 2005, Pages 163-174

  Go, Mae F ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; AZITHROMYCIN; BISMUTH; BISMUTH SALICYLATE; CLARITHROMYCIN; CYTOCHROME P450; DIAZEPAM; FLUCONAZOLE; FURAZOLIDONE; HELICOBACTER PYLORI VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; LANSOPRAZOLE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PENICILLIN G; PHENYTOIN; POTASSIUM ION; PROBIOTIC AGENT; PROTON; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; RIFABUTIN; TETRACYCLINE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; BEHAVIOR MODIFICATION; BREATH ANALYSIS; CHRONIC DISEASE; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DYSPEPSIA; FAMILY HISTORY; GASTROESOPHAGEAL REFLUX; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION CONTROL; INFLAMMATION; LIFESTYLE; NEUTROPENIA; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PEPTIC ULCER; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PREVALENCE; RASH; REVIEW; SOCIOECONOMICS; STOMACH CANCER; STOMACH LYMPHOMA; TASTE DISORDER; UVEITIS;

EID: 17444427388     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-005-0009-9     Document Type: Review

References (55)

1. Suerbaum S, Michetti P: Helicobacter pylori infection. N Engl J Med 2002, 347:1175-1186.
2. The Eurogast Study Group: Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. Gut 1993, 34:1672-1676.
3. Go MF: Epidemiology and natural history of H. pylori Aliment Pharmacol Ther 2002, 16(Suppl 1):3-15.
4. Vakil N, Vaira D: Non-invasive tests for the diagnosis of H. pylori infection. Rev Gastroenterol Dis 2004, 4: -6.
5. Gisbert JP, Pajares JM: Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter 2004, 9:347-368.
6. Gatta L, Perna F, Ricci C, et al.: A rapid immunochromatographic assay for Helicobacter pylori in stool before and after treatment. Aliment Pharmacol Ther 2004, 20: 69-474.
7. Gatta L, Vakil N, Ricci C, et al.: Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004, 99:823-829.
8. NIH Consensus Conference: Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994, 272:65-69.
9. Peura DA: The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology 1997, 113 (suppl):S4-S8.
10. Howden CW, Hunt RH: Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998, 93:2330-2338.
11. Malfertheiner P, Megraud F, O'Morain C, et al. and the European Helicobacter Pylori Study Group (EHPSG): Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002, 16:167-180.
12. Asaka M, Satoh K, Sugano K, et al.: Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 2001, 6:177-186.
13. Coelho LG, Leon-Barua R, Quigley EM: Latin-American consensus conference on Helicobacter pylori infection. Latin-American national gastroenterological societie affiliated with the Inter-American Association of Gastroenerotogie (AIGE). Am J Gastroenterol 2000, 95:2688-2691.
14. Hunt R, Fallone C, van Zanten SV, et al.: Canadian Helicobacter study group consensus conference: update on the management of Helicobacter pylori - an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H. pylori infection. Can J Gastroenterol 2004, 18:547-554.
15. Huang JQ, Sridhar S, Hunt RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002, 359: 4-22.
16. Hopkins RJ, Girardi LS, Turney EA: Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: A review. Gastroenterology 1996, 110: 244-1252.
17. Laine L, Sugg J: Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002, 97: 992-2997.
18. Raghunath AS, Hungin AP, Wooff D, Childs S: Systematic review: the effect of Helicobacter pylori and its eradication on gastro-esophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004, 20: 33-744.
19. Harvey RF, Lane JA, Murray LJ, et al.: Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-esophageal reflux: Bristol helicobacter project. BMJ 2004, 12:328:1417.
20. Holtmann G, Cain C, Malfertheiner P: Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterol 1999, 117:11-16.
21. Vakil NB, Traxler BM, Levine D: Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. Am J Gastroenterol 2004, 99:1437-1441.
22. De Wit NJ, De Boer WA, Geldof H, et al.: Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? Aliment Pharmacol Ther 2004, 20:451-458.
23. Huang JQ, Sridhar S, Chen Y, Hunt RH: Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998, 114:1169-1179.
24. International Agency for Research on Cancer: Schistosomes, liver flukes and Helicobacter pylori. In IARC Monographs Programme on the Evaluation of Carcinogenic Risks to Humans, vol 61. France: IARC; 1994.
25. A The Eurogast Study Group: An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993, 34:1359-1362.
26. Uemura N, Okamoto S, Yamamoto S, et al.: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345:784-789.
27. El-Omar EM, Carrington M, Chow WH, et al.: Interleukin-1 polymorphism associated with increased risk of gastric cancer. Nature 2000, 404:398-402.
28. El-Omar EM, Rabkin CS, Gammon MD, et al.: Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003, 124:1193-1201.
29. Talley NJ, Silverstein MD, Agreus L, et al.: AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology 1998, 114:582-595.
30. Chey WD, Moayyedi P: Uninvestigated dyspepsia and non-ulcer dyspepsia - the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy. Aliment Pharmacol Ther 2004, 19 (Suppl. 1):1-8.
31. Chiba N, Van Zanten SJ, Sinclair P, et al.: Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002, 324:1012-1016.
32. Moayyedi P, Feltbower R, Brown J, et al.: Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. Lancet 2000, 355:1665-1669.
33. Laine L, Schoenfeld P, Fennerty MB: Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001, 134:361-369.
34. Moayyedi P, Deeks J, Talley NJ, et al.: An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003, 98:2621-2626.
35. Sreedharan A, Clough M, Hemingbrough E, et al.: Cost-effectiveness and long-term impact of Helicobacter pylori "test and treat" service in reducing open access endoscopy referrals. Eur J Gastroenterol Hepatol 2004, 16:981-986.
36. Goodman KJ, Correa P, Tengana Aux HJ, et al.: Helicobacter pylori infection in the Colombian Andes: a population-based study of transmission pathways. Am J Epidemiol 1996, 144:290-299.
37. Correa P, Fontham ET, Bravo JC, et al.: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000, 92:1881-1888.
38. Wang K-Y, Li S-N, Liu C-S, et al.: Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr 2004, 80:737-741.
39. Johnson-Henry KC, Mitchell DJ, Avitzur Y, et al.: Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig Dis Sci 2004, 49: 095-1102.
40. Joossens JV, Hill MJ, Elliott P, et al.: Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group. Int J Epidemiol 1996, 25:494-504.
41. Murray LJ, Lane AJ, Harvey IM, et al.: Inverse relationship between alcohol consumption and active Helicobacter pylori infection: the Bristol Helicobacter project. Am J Gastroenterol 2002, 97:2750-2755.
42. Baena JM, Lopez C, Hidalgo A, et al.: Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. Eur J Gastroenterol Hepatol 2002, 14:291-296.
43. Vakil N, Lanza F, Schwartz H, Barth J: Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004, 20:99-107.
44. Juang JQ, Hunt RH: The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther 1999, 13:719-729.
45. McMahon BJ, Hennessy TW, Bensler JM, et al.: The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003, 139:463-469.
46. Meyer JM, Silliman NP, Wang W, et al.: Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002, 136:13-24.
47. Laine L, Hunt R, El-Zimaity H, et al.: Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003, 98:562-567.
48. Perri F, Festa V, Clemente R, et al.: Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000, 14:311-316.
49. Pilotto A, Franceschi M, Rassu M, et al.: In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. Am J Gastroenterol 2000, 95:833-834.
50. Gisbert JP, Pajares JM: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002, 16:1047-1057.
51. Graham DY, Osato M, Hoffman I, et al.: Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 2000, 14:211-215.
52. Fakheri H, Merat S, Hosseini V, Malekzadeh R: Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004, 19:89-93.
53. Bosques-Padilla FJ, Garza-Gonzalez E, Calderon-Lozano I, et al.: Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs 14 day treatment. Helicobacter 2004, 9: 17-421.
54. Gatta L, Ricci C, Zulla A, et al.: High eradication rate with a rescue levofloxacin based treatment for Helicobacter pylori [Abstract]. Gastroenterol 2004, 126:A74.
55. Michetti P, Svennerholm AM: Helicobacter pylori inflammation, immunity and vaccines. Helicobacter 2003, 9 (Suppl 1):31-35.